• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

    3.045 -3.375 (-52.57%)
    Streaming Delayed Price Updated: 1:44 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,515,952
    Open 3.112
    Bid (Size) 3.040 (500)
    Ask (Size) 3.050 (300)
    Prev. Close 6.420
    Today's Range 2.830 - 3.260
    52wk Range 5.880 - 15.74
    Shares Outstanding 61,758,994
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    These stocks are moving in today's session ↗
    Via Chartmill
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill

    Performance

    YTD
    -72.1%
    -72.1%
    1 Month
    -56.6%
    -56.6%
    3 Month
    -61.0%
    -61.0%
    6 Month
    -69.1%
    -69.1%
    1 Year
    -56.2%
    -56.2%

    More News

    Read More
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Which stocks are moving after the closing bell on Monday? ↗
    Via Chartmill
    Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism ↗
    Via Chartmill
    Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗
    Via Chartmill
    News headline image
    Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum (FULC) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    Via MarketMinute
    News headline image
    Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
    Via MarketMinute
    News headline image
    MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
    Via AB Newswire

    Frequently Asked Questions

    Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
    Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
    The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
    What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
    The current price of Fulcrum Therapeutics, Inc. - Common Stock is 3.045
    When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
    The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 06/02/26 01:44 PM ET
    What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
    The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 188.06M
    How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
    Fulcrum Therapeutics, Inc. - Common Stock has 188M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.